Ardelyx reports Q1 2022 net loss of $28.1M; first IBSRELA sales of $0.5M

ARDELYX, INC.

2022-Q1 EPS reported -$0.21 revenue$468,000

First commercial sales of IBSRELA for IBS-C generated $0.5M in March 2022.
Net loss $28.1M ($0.21 per share) vs $33.2M ($0.34 per share) YoY improvement.
Cash & investments $89.7M at March 31, 2022, down from $116.7M at Dec 31, 2021.
FDA to convene advisory committee for XPHOZAH (phosphate binder) for hyperphosphatemia in CKD on dialysis.
Amended Kyowa Kirin deal: up to $40M additional milestones; royalty rate reduced from high teens to low double digits.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.